Pathogenesis of anaemia in hyperparathyroidism

Medical Hypotheses

Volumn 54, Issue 2, 2000, Pages 236-238

  Sikole, A ^a  

^a SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; PARATHYROID HORMONE;

ANEMIA; BONE MARROW CELL; CHRONIC KIDNEY FAILURE; ERYTHROCYTE COUNT; ERYTHROID CELL; ERYTHROPOIESIS; HORMONE SYNTHESIS; HUMAN; HYPERPARATHYROIDISM; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SHORT SURVEY; STEM CELL;

EID: 0034018550     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0027     Document Type: Article

References (21)

1. Boxer M., Ellman L., Geller R., Wang C. A. Anaemia in primary hyperparathyroidism. Arch Intern Med. 137:1977;588-590.
2. Falko J. M., Guy J. T., Smith R. E., Mazzaferri E. L. Primary hyperparathyroidism and anaemia. Arch Intern Med. 136:1976;887-889.
3. Mallette L. E., Bilezikian J. P., Heath D. A. Primary hyperparathyroidism: clinical and biochemical features. Medicine. 53:1974;127-146.
4. Massry S. G. Pathogenesis of the anaemia of uremia: role of secondary hyperparathyroidism. Kidney Int. 24:1983;204-207.
5. Zingraff J., Drueke T., Marie P., Man N. K., Jungers P., Bordier P. Anaemia and secondary hyperparathyroidism. Arch Intern Med. 138:1978;1650-1652.
6. Eschbach J. W. the anaemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 35:1989;134-148.
7. Miyake T., Kung C. K. H., Goldwasser E. Purification of human erythropoietin. J Biol Chem. 252:1977;5558-5564.
8. Jacobs K., Shoemaker C., Rudersdorf R. Isolation and characterisation of genomic and cDNA clones of human erythropoietin. Nature. 313:1985;806-810.
9. Bondurant M., Kelley L., Koury M. J. Is erythropoietin a differentiation factor, a mitotic factor, or a survival factor? Bauer C., Koch K. M., Scigalla P., Wieczorek L. Erythropoietin: Molecular Physiology and Clinical Application. 1993;Marcel Dekker, New York.
10. Koury M. J., Bondurant M. C. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid cells. Science. 248:1990;378.
11. Spivak J. L., Pham T., Isaacs M., Hankins W. D. Erythropoietin is both a mitogen and a survival factor. Blood. 77:1991;1228.
12. Meytes D., Bogin E., Ma A., Dukes P. P., Massry S. G. Effect of parathyroid hormone on erythropoiesis. J Clin Invest. 67:1981;1263-1269.
13. Bogin E., Massry S. G., Levi J., Djaldelli M., Bristol G., Smith J. Effect of parathyroid hormone on osmotic fragility of human erythrocytes. J Clin Invest. 69:1982;1017-1025.
14. Lerche D., Schmidt R., Zoellner K. Rheology in whole blood and in red blood cells under recombinant human erythropoietin therapy. Contrib Nephrol. 76:1989;299-305.
15. Polenakovic M., Sikole A. Is erythropoietin a survival factor for the red blood cells? J Am Soc Nephrol. 7:1996;1178-1182.
16. Schwartz A. B., Kelch B., Terzian L. One year of rhuEPO therapy prolongs RBC survival and may stabilize RBC membranes despite natural progression of chronic renal failure to uremia and need for dialysis. ASAIO Trans M692, 1990.
17. Hughes R. T., Cotes P. M., Pippard M. J. Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: an erythrokinetic assessment. Br J Haematol. 75:1990;268-273.
18. Magocsi M., Takacs S., Apati A., Nazem A. K., Mako J. Calcitriol enhances the effect of Rh-Epo on erythroid differentiation. Int J Artificial Organs. 20:1997;502.
19. Rao D. S., Shih M., Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med. 328:1993;171-175.
20. Caro J. S., Brown S., Miller O., Murray T., Erslev A. J. Erythropoietic levels in uremic nephric and anephric patients. J Lab Clin Med. 93:1979;449-458.
21. Tulliez M., Picard F., Casadevall N. Human recombinant erythropoietin does not induce bone marrow fibrosis in haemodialysed patients. Nephrol Dial Transplant. 4:1989;674-675.